NCT06785116View on ClinicalTrials.gov

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 2, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Gestational HypertensionHypertension in PregnancyPre-EclampsiaSuperimposed Pre-EclampsiaCardiovascular Complication
Interventions
DRUG

Placebo

Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.

DRUG

Dapagliflozin 10mg Tab

Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.

Trial Locations (1)

48109

RECRUITING

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

Society for Maternal-Fetal Medicine Foundation

UNKNOWN

collaborator

American Association of Obstetricians and Gynecologists Foundation

UNKNOWN

lead

University of Michigan

OTHER